These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 36849760)

  • 1. Long-term safety and efficacy of velmanase alfa treatment in children under 6 years of age with alpha-mannosidosis: A phase 2, open label, multicenter study.
    Guffon N; Konstantopoulou V; Hennermann JB; Muschol N; Bruno I; Tummolo A; Ceravolo F; Zardi G; Ballabeni A; Lund A
    J Inherit Metab Dis; 2023 Jul; 46(4):705-719. PubMed ID: 36849760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive long-term efficacy and safety of recombinant human alpha-mannosidase (velmanase alfa) treatment in patients with alpha-mannosidosis.
    Lund AM; Borgwardt L; Cattaneo F; Ardigò D; Geraci S; Gil-Campos M; De Meirleir L; Laroche C; Dolhem P; Cole D; Tylki-Szymanska A; Lopez-Rodriguez M; Guillén-Navarro E; Dali CI; Héron B; Fogh J; Muschol N; Phillips D; Van den Hout JMH; Jones SA; Amraoui Y; Harmatz P; Guffon N
    J Inherit Metab Dis; 2018 Nov; 41(6):1225-1233. PubMed ID: 29725868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enzyme replacement therapy with velmanase alfa (human recombinant alpha-mannosidase): Novel global treatment response model and outcomes in patients with alpha-mannosidosis.
    Harmatz P; Cattaneo F; Ardigò D; Geraci S; Hennermann JB; Guffon N; Lund A; Hendriksz CJ; Borgwardt L
    Mol Genet Metab; 2018 Jun; 124(2):152-160. PubMed ID: 29716835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between
    Borgwardt LG; Ceravolo F; Zardi G; Ballabeni A; Lund AM
    JIMD Rep; 2023 Mar; 64(2):187-198. PubMed ID: 36873087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of Velmanase alfa in the treatment of patients with alpha-mannosidosis: results from the core and extension phase analysis of a phase III multicentre, double-blind, randomised, placebo-controlled trial.
    Borgwardt L; Guffon N; Amraoui Y; Dali CI; De Meirleir L; Gil-Campos M; Heron B; Geraci S; Ardigò D; Cattaneo F; Fogh J; Van den Hout JMH; Beck M; Jones SA; Tylki-Szymanska A; Haugsted U; Lund AM
    J Inherit Metab Dis; 2018 Nov; 41(6):1215-1223. PubMed ID: 29846843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The SPARKLE registry: protocol for an international prospective cohort study in patients with alpha-mannosidosis.
    Hennermann JB; Guffon N; Cattaneo F; Ceravolo F; Borgwardt L; Lund AM; Gil-Campos M; Tylki-Szymanska A; Muschol NM
    Orphanet J Rare Dis; 2020 Sep; 15(1):271. PubMed ID: 32993743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can velmanase alfa be the next widespread potential therapy for alpha-mannosidosis?
    Abdul Ghani S; Burney S; Ul Hussain H; Abdul Wahid M; Mumtaz H
    Int J Surg; 2023 Sep; 109(9):2882-2885. PubMed ID: 37352513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnosis of alpha-Mannosidosis: Practical approaches to reducing diagnostic delays in this ultra-rare disease.
    Santoro L; Cefalo G; Canalini F; Rossi S; Scarpa M
    Mol Genet Metab; 2024 May; 142(1):108444. PubMed ID: 38555683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hearing impairment as an early sign of alpha-mannosidosis in children with a mild phenotype: Report of seven new cases.
    Lehalle D; Colombo R; O'Grady M; Héron B; Houcinat N; Kuentz P; Moutton S; Sorlin A; Thevenon J; Delanne J; Gay S; Racine C; Garde A; Tran Mau-Them F; Philippe C; Vitobello A; Nambot S; Huet F; Duffourd Y; Feillet F; Thauvin-Robinet C; Marlin S; Faivre L
    Am J Med Genet A; 2019 Sep; 179(9):1756-1763. PubMed ID: 31241255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early biochemical effects of velmanase alfa in a 7-month-old infant with alpha-mannosidosis.
    Santoro L; Zampini L; Padella L; Monachesi C; Zampieri S; Dardis A; Cordiali R; Galeazzi T; Catassi C
    JIMD Rep; 2020 Sep; 55(1):15-21. PubMed ID: 32905047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Caregivers' and Physicians' Perspectives on Alpha-Mannosidosis: A Report from Italy.
    Verrecchia E; Sicignano LL; Massaro MG; Rocco R; Silvestri G; Rossi S; Manna R
    Adv Ther; 2021 Jan; 38(1):1-10. PubMed ID: 33231860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of the Bruininks-Oseretsky test of motor proficiency (BOT-2) to assess efficacy of velmanase alfa as enzyme therapy for alpha-mannosidosis.
    Phillips D; Hennermann JB; Tylki-Szymanska A; Borgwardt L; Gil-Campos M; Guffon N; Amraoui Y; Geraci S; Ardigò D; Cattaneo F; Lund AM
    Mol Genet Metab Rep; 2020 Jun; 23():100586. PubMed ID: 32292699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enzyme replacement therapy for alpha-mannosidosis: 12 months follow-up of a single centre, randomised, multiple dose study.
    Borgwardt L; Dali CI; Fogh J; Månsson JE; Olsen KJ; Beck HC; Nielsen KG; Nielsen LH; Olsen SO; Riise Stensland HM; Nilssen O; Wibrand F; Thuesen AM; Pearl T; Haugsted U; Saftig P; Blanz J; Jones SA; Tylki-Szymanska A; Guffon-Fouiloux N; Beck M; Lund AM
    J Inherit Metab Dis; 2013 Nov; 36(6):1015-24. PubMed ID: 23494656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lysosomal alpha-mannosidase and alpha-mannosidosis.
    Paciotti S; Codini M; Tasegian A; Ceccarini MR; Cataldi S; Arcuri C; Fioretti B; Albi E; Beccari T
    Front Biosci (Landmark Ed); 2017 Jan; 22(1):157-167. PubMed ID: 27814608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enzyme replacement therapy in alpha-mannosidosis guinea-pigs.
    Crawley AC; King B; Berg T; Meikle PJ; Hopwood JJ
    Mol Genet Metab; 2006; 89(1-2):48-57. PubMed ID: 16807033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural history of alpha mannosidosis a longitudinal study.
    Beck M; Olsen KJ; Wraith JE; Zeman J; Michalski JC; Saftig P; Fogh J; Malm D
    Orphanet J Rare Dis; 2013 Jun; 8():88. PubMed ID: 23786919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety, immunogenicity, and clinical outcomes in patients with Morquio A syndrome participating in 2 sequential open-label studies of elosulfase alfa enzyme replacement therapy (MOR-002/MOR-100), representing 5 years of treatment.
    Hendriksz C; Santra S; Jones SA; Geberhiwot T; Jesaitis L; Long B; Qi Y; Hawley SM; Decker C
    Mol Genet Metab; 2018 Apr; 123(4):479-487. PubMed ID: 29526614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Application of HPLC-FLD and NMR in the Monitoring of Therapy Efficacy in Alpha-Mannosidosis.
    Krchňák M; Kodríková R; Matulová M; Nemčovič M; Uhliariková I; Katrlík J; Šalingová A; Hlavatá A; Juríčková K; Baráth P; Mucha J; Pakanová Z
    Front Biosci (Landmark Ed); 2023 Feb; 28(2):39. PubMed ID: 36866557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alpha-Mannosidosis: Therapeutic Strategies.
    Ceccarini MR; Codini M; Conte C; Patria F; Cataldi S; Bertelli M; Albi E; Beccari T
    Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29772816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted disruption of the lysosomal alpha-mannosidase gene results in mice resembling a mild form of human alpha-mannosidosis.
    Stinchi S; Lüllmann-Rauch R; Hartmann D; Coenen R; Beccari T; Orlacchio A; von Figura K; Saftig P
    Hum Mol Genet; 1999 Aug; 8(8):1365-72. PubMed ID: 10400983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.